ANI Pharmaceuticals Future Growth

Future criteria checks 3/6

ANI Pharmaceuticals is forecast to grow earnings and revenue by 37.3% and 6.1% per annum respectively while EPS is expected to grow by 35.6% per annum.

Key information

37.3%

Earnings growth rate

35.6%

EPS growth rate

Pharmaceuticals earnings growth	23.6%
Revenue growth rate	6.1%
Future return on equity	n/a
Analyst coverage	Low
Last updated	30 Apr 2024

Recent future growth updates

Recent updates

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15

Earnings and Revenue Growth Forecasts

NasdaqGM:ANIP - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	609	53	122	177	4
12/31/2025	576	35	105	142	5
12/31/2024	535	23	107	141	5
12/31/2023	487	15	100	119	N/A
9/30/2023	449	10	53	70	N/A
6/30/2023	401	-8	19	41	N/A
3/31/2023	359	-28	-7	9	N/A
12/31/2022	316	-50	-48	-31	N/A
9/30/2022	283	-69	-53	-39	N/A
6/30/2022	251	-65	-52	-48	N/A
3/31/2022	226	-63	-61	-36	N/A
12/31/2021	216	-43	-20	3	N/A
9/30/2021	212	-22	-16	10	N/A
6/30/2021	213	-17	-17	14	N/A
3/31/2021	213	-15	23	34	N/A
12/31/2020	208	-23	-53	15	N/A
9/30/2020	199	-24	-42	26	N/A
6/30/2020	198	-20	-15	49	N/A
3/31/2020	203	-1	-32	33	N/A
12/31/2019	207	6	18	46	N/A
9/30/2019	216	16	41	68	N/A
6/30/2019	215	17	28	55	N/A
3/31/2019	208	14	30	58	N/A
12/31/2018	202	15	56	67	N/A
9/30/2018	192	0	-4	56	N/A
6/30/2018	189	0	3	64	N/A
3/31/2018	187	0	-1	56	N/A
12/31/2017	177	-1	-69	39	N/A
9/30/2017	168	7	N/A	36	N/A
6/30/2017	158	5	N/A	20	N/A
3/31/2017	145	4	N/A	23	N/A
12/31/2016	129	4	N/A	27	N/A
9/30/2016	108	8	N/A	20	N/A
6/30/2016	90	10	N/A	29	N/A
3/31/2016	78	12	N/A	27	N/A
12/31/2015	76	15	N/A	17	N/A
9/30/2015	79	33	N/A	23	N/A
6/30/2015	77	35	N/A	17	N/A
3/31/2015	64	30	N/A	18	N/A
12/31/2014	56	29	N/A	22	N/A
9/30/2014	45	11	N/A	8	N/A
6/30/2014	36	5	N/A	3	N/A
3/31/2014	35	1	N/A	0	N/A
12/31/2013	30	-5	N/A	-5	N/A
9/30/2013	25	-12	N/A	-3	N/A
6/30/2013	22	-16	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANIP's forecast earnings growth (37.3% per year) is above the savings rate (2.4%).

Earnings vs Market: ANIP's earnings (37.3% per year) are forecast to grow faster than the US market (14.4% per year).

High Growth Earnings: ANIP's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ANIP's revenue (6.1% per year) is forecast to grow slower than the US market (8.3% per year).

High Growth Revenue: ANIP's revenue (6.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ANIP's Return on Equity is forecast to be high in 3 years time

ANI Pharmaceuticals Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Consensus EPS estimates increase by 27%

Price target increased by 7.5% to US$75.50

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

Price target increased by 12% to US$55.00

Recent updates

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Consensus EPS estimates increase by 27%

Independent Director notifies of intention to sell stock

Price target increased by 7.5% to US$75.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

Head of R&D notifies of intention to sell stock

Head of R&D notifies of intention to sell stock

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Head of Rare Disease recently sold US$157k worth of stock

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals, Inc. Announces Board Changes

Head of R&D notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Profitability

Head of R&D notifies of intention to sell stock

Price target increased by 12% to US$55.00

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million.

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023

Consensus EPS estimates fall by 42%, revenue upgraded

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.7% to US$46.60

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Levocarnitine Tablets USP

ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Trimethoprim Tablets USP

Consensus forecasts updated

High number of new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ani Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2022

We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

ANI Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

ANI Pharmaceuticals, Inc. Appoints Krista Davis as Chief Human Resources Officer

ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP

ANI Pharma launches generic Prochlorperazine maleate tablets

Key Executive notifies of intention to sell stock

Key Executive recently sold US$673k worth of stock

ANI Pharmaceuticals, Inc. Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP

ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval

Consensus forecasts updated

ANI Pharmaceuticals, Inc. Reports Impairment Charge for the Second Quarter Ended June 30, 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

ANI Pharmaceuticals Q2 2022 Earnings Preview

Ani Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP

ANI Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022